Amedica has announced that they are to present the 24-month clinical results of the CASCADE trial on 7 March 2016.
The blinded, randomised clinical trial compared spinal fusion between its composite silicon nitrade fusion devices with a central, cancellous core, to PEEK spaces filled with bone autograft.
The results will be presented through a conference call and a live webcast available on the company website. Mark P Arts, a neurosurgeon from the Medical Centre Haaglanden, The Hague, Netherlands and principal investigator of the trial will present the data, and Sonny Bal, chairman and chief executive officer of Amedica will discuss its impact on business.
